Alan Lombard, Ph.D.
Department of Biochemistry and Molecular Medicine
Department of Urologic Surgery
2700 Stockton Blvd.
Research in the Lombard Lab focuses on identifying and targeting the mechanisms of prostate tumor progression, with the goal of enhancing therapeutic efficacy and designing novel strategies to improve patient outcomes. The clinical landscape for the management of prostate cancer is rapidly changing. Next-generation anti-androgens have significantly improved androgen receptor targeting, and the addition of novel agents, including PARP inhibitors, has greatly augmented our ability to treat advanced disease. Despite this progress, patients still progress. We employ a multi-pronged strategy including 1) development and utilization of in vitro and in vivo models, 2) molecular/cellular biological, biochemical, and omics approaches, and 3) bioinformatics to understand the underlying mechanisms of tumor biology and response and resistance to therapy. Our goal is to incorporate novel findings into the design of efficacious treatments.
Graduate Group Affiliations
Gao AC, Ning S, Liu C, Lou W, Yang JC, Lombard AP, et al. Bioengineered BERA-Wnt5a siRNA targeting Wnt5a/FZD2 signaling suppresses advanced prostate cancer tumor growth and enhances enzalutamide treatment. Mol Cancer Ther 2022 doi 10.1158/1535-7163.MCT-22-0216.
Lombard A. P. et al (2021). “Olaparib-Induced Senescence is Bypassed through G2-M Checkpoint Override in Olaparib-Resistant Prostate Cancer.” Mol Cancer Ther 21(4): 677-685.
Lombard, A. P., W. Lou, C. M. Armstrong, L. S. D'Abronzo, S. Ning, C. P. Evans and A. C. Gao (2021). "Activation of the ABCB1 Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer Cells." Mol Cancer Ther 20(10): 2061-2070.
Katleba, K., A. P. Lombard, M. M. Tsamouri, H. B. Baek, K. S. Nishida, S. J. Libertini, A. J. Platero, A. H. Ma, C. X. Pan, P. M. Ghosh and M. Mudryj (2021). "Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis." Cancer Lett 504: 49-57.
Armstrong, C. M., C. Liu, L. Liu, J. C. Yang, W. Lou, R. Zhao, S. Ning, A. P. Lombard, J. Zhao, L. S. D'Abronzo, C. P. Evans, P. K. Li and A. C. Gao (2020). "Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer." Clin Cancer Res 26(22): 6064-6074.
Lombard, A.P. and A.C. Gao, Resistance Mechanisms to Taxanes and PARP Inhibitors in Advanced Prostate Cancer. Curr Opin Endocr Metab Res, 2020. 10: p. 16-22.
Lombard, A. P., C. Liu, C. M. Armstrong, L. S. D'Abronzo, W. Lou, C. P. Evans and A. C. Gao (2019). "Wntless promotes cellular viability and resistance to enzalutamide in castration-resistant prostate cancer cells." Am J Clin Exp Urol 7(4): 203-214.
Lombard, A. P., C. Liu, C. M. Armstrong, L. S. D'Abronzo, W. Lou, H. Chen, M. Dall'Era, P. M. Ghosh, C. P. Evans and A. C. Gao (2019). "Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer." Transl Oncol 12(7): 871-878.
Liu, C., W. Lou, J. C. Yang, L. Liu, C. M. Armstrong, A. P. Lombard, R. Zhao, O. D. V. Noel, C. G. Tepper, H. W. Chen, M. Dall'Era, C. P. Evans and A. C. Gao (2018). "Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer." Nat Commun 9(1): 4700.
Lombard, A. P., L. Liu, V. Cucchiara, C. Liu, C. M. Armstrong, R. Zhao, J. C. Yang, W. Lou, C. P. Evans and A. C. Gao (2018). "Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer." Mol Cancer Ther 17(10): 2197-2205.
- (2022) Campos Faculty Scholar (8th Cohort), UC Davis Office of DEI
- (2021) Eddie Mendez Scholar Award, Fred Hutchinson Cancer Research Center
- (2020) Society for Basic Urologic Research (SBUR) Travel Award
- (2018) Society for Basic Urologic Research (SBUR) Travel Award
- (2016) Society for Basic Urologic Research (SBUR) Travel Award